Medsafe consultation submission

Change to warning statements on labels of OTC loratadine and desloratadine medicines

Name and designation	
Company/organisation name and address	
Contact phone number and email address	

I would like the comments I have provided to be kept confidential: *(Please give reasons and identify specific sections of response if applicable)* (Reasons for requesting confidentiality must meet Official Information Act 1982 criteria)	☐ Yes ☐ No
I would like my name to be removed from all documents prior to publication on the Medsafe website.	☐ Yes ☐ No
I would like for my name not to be included within the list of submissions published on the Medsafe website.	☐ Yes ☐ No

It would help in the analysis of stakeholder comments if you provide the information requested below.

I am, or I represent, an organisation that is based in:

☐ New Zealand ☐ Australia ☐ Other (*please specify*):

I am, or I represent, a: *(tick all that apply)*

☐ Importer ☐ Manufacturer ☐ Supplier ☐ Sponsor

☐ Government ☐ Researcher ☐ Professional body ☐ Industry organisation

☐ Consumer organisation ☐ Member of the public ☐ Institution (e.g. university, hospital)

☐ Regulatory affairs consultant ☐ Laboratory professional

☐ Health professional – *please indicate type of practice*:

☐ Other - *please specify*:

Please return this form to:

Email: **medsafeapplications@moh.govt.nz** including 'Loratadine warning statements' in the subject line

Or Post: Product Regulation
Medsafe
PO Box 5013
Wellington 6145

Medsafe is seeking comments on:

Change to the warning statement for OTC loratadine and desloratadine:

- Is the proposed warning statement appropriate?

1 March 2017 - target date for implementation:

- Is the target date for implementation in New Zealand reasonable?

Please include additional pages if necessary.